Introduction Since April 2007, health insurance companies in Germany have been entitled to negotiate drug discount contracts (DDCs) with pharmaceutical manufacturers for particular drugs. DDCs commit pharmacists to dispense the drug made by this manufacturer. The aim of this study was to examine how DDCs are implemented in pharmacy routines and what implications DDCs have for the everday drug supply. Methods A standardized questionnaire on DDCs and their impact on the drug supply was developed according to the previous literature, piloted and distributed to pharmacies in Baden-Württemberg. Results Eight hundred four pharmacists and pharmaceutical assistants participated in the study. The implementation of DDCs implies significant extra work for pharmacists, particulary the additional need for customer counseling and education (99.1%), additional logistical requirements and more complex data processing needs. Patients are reported to get confused (97%) and angry (96.9%) about non-transparent drug substitutions, and medication errors occur (60.1%). Conclusion DDCs, besides having implications for prescibers and patients, also have a substantial impact on pharmacists and pharmacies. Adverse effects on the drug supply and medication safety are possible or likely.
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Background
In Germany, a recently (April 2007) reformed federal Health Insurance Act (Sozialgesetzbuch 5, SGB V) entitles health insurance companies to make contracts with pharmaceutical manufacturers stipulating that participants in the insurance programs purchase the contract partner's drug if an active ingredient regulated by the contract is prescribed. If a patient has a prescription for a brand name drug from a different manufacturer than the contract partner, pharmacists are instructed not to hand out the prescribed drug but rather the drug from the contract partner according to certain substitution rules listed below. Doctors may bypass the regulation for medical reasons by prescribing a brand name drug and ticking the 'aut-idem tickbox' in the prescription form, assuring that an individual patient receives a particular brand name drug, but discharging the health insurance company in part from their obligation to pay for the drug.
The aim of the legal regulation is to reduce expenses by using cheaper drug supplies.
Substitution rules include -identical active ingredient -identical dosage -identical package size -same indication and the same or exchangeable galenics. The composition of additives (e.g., alcohol, allergens, etc.) and also splitting properties of tablets to be substituted may vary (Pruszydlo et al. 2008 ).
Despite detailed substitution rules, patients have to face frequent changes in drug design and packaging.
There is evidence that substitution of drugs may result in patient confusion and medication errors (De Smet et al. 2007; Brekke et al. 2008; Sorensen et al. 2006) , and that consultations with prescribing physicians are necessary (Hibbeler 2007 (Maag 2009 ). The logistics and management of substitutions for such a huge number of drugs are growing more complex and actually mean that more than 18 million data sets have to be considered in any prescription (Keller 2008) . Also, logistics for the procurement of drugs has become more complex and more prone to errors. At the time when the first contracts started, there were often difficulties in the delivery from the pharmaceutical manufacturers. The storage capacity of pharmacies had to be extended (Hibbeler 2007) .
Patients might be confused or feel frightened if they receive drugs with a modified package, similar drug names and tablets in a different shape, color or divisibility than the one used before (Aronson 2004) . Medication errors have been reported, the need for additional diagnostic and therapeutic procedures has been suspected, and a substantial individual health impact cannot be excluded (Krämer et al. 2008; Meyer 2009; Otterbach 2008) .
Additional information needs and guidance cause increasing service times in pharmacies with an impact on patient/customer satisfaction. Also, pharmacy customers get annoyed about long waiting times because they need additional guidance or their drug is not available. The relationship between the customer and pharmacist as well as drug adherence might suffer.
So far, data on the impact of drug discount contracts on pharmacists, physicians and patients are sparse. The aim of this study was to investigate how DDCs are implemented and what impact they have. To have an overview of their effects, affected groups, i.e., patients, doctors and pharmacists, were interviewed by self-administered questionnaire about their experience with these contracts. The results of two studies have been submitted for publication. Here, data about the impact of drug discount contracts on pharmacies and on patients' drug supplies are reported.
Methods
For an overview of previous research on drug discount contracts, a literature search of MEDLINE, EMBASE and COCHRANE was performed using the keywords "drug discount contracts" or "compliance" or "tablet splitting," "drug switching" or "generic substitution" or "aut idem" or "adherence." In addition, a manual search of Germanlanguage journals such as "Zeitschrift für Allgemeinmedizin," "Deutsche Ärztezeitung" or the "Pharmazeutische Zeitung" was done.
Based on this literature review and in collaboration with pharmacists, a questionnaire for pharmacies was developed and piloted in an iterative process. The survey instrument contains sociodemographic data such as age, gender, profession and years of professional practice and data about the environment of the pharmacy. Participants were asked about what impact drug discount contracts have on their daily work, their difficulties with respect to staff and storage of the additional drugs, their need for information and the way the patients handled the substitutions. Questions were answered by Likert-type answering scales ("true," "likely to be true," "tend not to be true" and "does not apply to") (Jamieson 2004) .
The questionnaire was distributed as a supplement in the member journal "Landesapothekenkammer BadenWürttemberg" (Regional Chamber of Pharmacists) called "COSMAS" and was sent out by the group to approximately 2,750 pharmacies in Baden-Württemberg. The questionnaire was returned anonymously to the authors.
The study was approved by the university's internal review board (no. 190/08).
Data processing and statistics
Data were entered in a SAS database randomly controlled for correct input and evaluated by means of descriptive statistics. All variables were initially evaluated descriptively, and analytical statistics were performed if applicable.
Results
The survey was conducted between September-December 2008. Eight hundred four questionnaires were returned from pharmacists (82.3%), PTAs (pharmacist's assistants, 13.7%) and PKAs (pharmaceutical sales assistants) or other professions (4%; PKAs/other). Thirty-eight percent of respondents were male.
In Table 1 , basic characteristics of the sample are presented.
Further on, responses are reported without reference to professional level, unless otherwise noted.
Presentation of individual items
A substantial majority of respondents (69%) reported that they rarely get prescriptions that exclude substitutions ("aut-idem tickbox" ticked), and 30.9% reported they had received some such presciptions.
According to the pharmacists' questionnaire, they usually (82.5% on a Likert scale) receive prescriptions with the drug's brand name on it. In contrast to other European countries, German pharmacists seldom receive prescriptions with the drug's active ingredient noted (79.8% rejection on a Likert scale; Fig. 1) .
The vast majority of respondents (98.3%) often had needed to switch drugs because of DDCs, and almost half of them (45.3%) admitted that they occasionally did not have appropriate drugs for substitution in stock; 45.1% reported shortages of supplies of appropriate drugs, and some 31% had encountered delivery problems with these drugs. Less than one fourth did not have substantial (21.6%) or did not have any (1.9%) supply problems with discount drugs.
One of the critiques against drug substitution is that splitting properties of tablets might differ substantially; 65.7% (48.4 + 17.3) of pharmacists or their employees did not have precise information about the splitting properties of individual drugs given to patients (Fig. 2) .
Almost all respondents (96.9%) reported that customers had reacted angrily about getting an unknown drug. Ninetyseven percent of interviewees noted that in their opinion the patients felt confused about how to handle their drugs because of DDCs. Furthermore, 60.1% of respondents specified that they knew about medication errors of patients because of DDCs (Fig. 3) . The vast majority (99.1%) reported increased need for patient counseling; 99.3% stated that the discount contracts have had an important impact on daily business. Of them, 93.8% indicated additional personnel expenses because of additional delivery of servives concerning drugs to the patients. In Germany if a specific drug is not in stock in the pharmacy, it is ordered, and the medication will be delivered to the patient's home, usually on the same day (Fig. 4) .
In Table 2 , we present the results concerning extra payments, customer behavior with respect to swapping drugs and additional patient waiting time because of DDCs.
About 85% (24.5% and 59.9%, respectively) of the respondents noted that patients asked not to substitute their previously known drug more than five times a week, and 70% (27.9% and 42.2%, respectively) said that at least five times a week customers not only asked for, but insisted on receiving their known drug. Likewise, customers had to accept additional waiting times because of increased counseling and occasionally even higher surcharges. Furthermore, over 70% reported that they were threated with repayments ("Retaxierung") by the health insurance companies up to ten times per month (Table 2) . The administration of drug discount contracts includes a significant additional burden for pharmacies. This is primarily due to the significant demand for explanations by the patients, manpower requirements, challenging logistics and the technical processing of data. Additional personnel expenses because of an additional service (delivery service) and a large increase in the need for advice by the customers have an important influence on the daily business. Also, half of the pharmacists do not know exactly if the substitution tablet is as good and can be divided as precisely the substituted one was. They additionally have to look this information up in the Formulary. Pharmacists have an increased demand for providing patient information and consultations because of the discount contracts.
Not only pharmacists bear an additional burden because of the DDCs. Patients experienced the same inconvenience. Medication errors do occur (Rücker et al.; Mahler et al) . It is evident that patients feel confused and angry because of the substitution (Rücker 2007; Wahl 2008) . This is also reflected in the patients' interactions with the pharmacists, because patients very often insist on or ask for their wellknown medicine. Patients have longer waiting times because the pharmicists have to give more additional advice and also because of delivery problems of the pharmaceutical companies (Haffke 2008) .
Physicians might specify that the priscribed drug on the prescription form should not be changed to make sure that the patient continues to receive his usual medication. According to surveys by the "Kassenärztlichen Vereinigung Nordrhein" (Association of Statutory Health Insurance Physicians, North Rhine), the majority of physicians never or only in individual cases tick the box "aut idem" (Neye 2008 ). This may be because physicians are held liable for uneconomical prescriptions by the health insurance companies (Manthey 2008) . The same applies for pharmacists. If they do not deliver the particular rebate drugs of the health insurance companies' contractors, they might be held liable in a procedure called "Retaxierung" for additional costs for non-contractors' drugs by the health insurance companies (Ehlers and Weizel 2001) . Now, with DCCs in effect, health insurance companies directly interfere with historically evolved structures in the health care system. DCCs impose a fundamental reorganization of Germany's drug supply by administrative means. Pharmacies' and pharmacists' self-concepts and relationships to customers have been fundamentally changed.
In the long run, pharmacies in Germany might have to give up their traditional role as an independent player and stakeholder in the health care system and become more of a "dispensary-style" pharmacy that hands out a drug after first negotiating between health care companies and drug manufacturers.
Limitations of the study A fundamental limitation of this study is the restriction to self-reported evaluation of the impact of DDCs on pharmacists' attitudes about the medication supply and to self-reported behavior. No direct observations of pharmacists were made, and the reliability of the pharmacists' statements is unknown. In this study, patients' attitudes have only been reported by the best guess of pharamacists, and no direct patient-generated data were part of this manuscript. Data about physicians' and patients' selfreported attitudes are reported elsewhere.
Due to a lack of basic data, this study could not be designed to evaluate the size of the effect of DDCs on patients' drug supplies, medication adherence, potential adverse events and well-being.
Conclusion
The DDCs denote a significant intervention in drug therapy. Pharmacists report on medication errors by the patients because of the discount contracts. Medication safety seems to be at risk. Further studies, e.g., analysis of secondary data and direct observations, are necessary to evaluate the effect of these contract agreements. The aim of the discount contracts should not focus on monetary aspects alone. One of the major ethical aims of modern medicine is respect for patients' autonomy, and this might be affected by DDCs.
